Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis - Takeaway - MDSpire
From the Journals
Clinical Guidelines

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

Results from a small phase II study suggest that a triplet regimen may improve symptoms and extend survival in some patients with breast cancer and leptomeningeal metastasis, who often face limited tr...

Share

  • 1

    Study evaluated therapy for leptomeningeal metastasis in breast cancer.

  • 2

    Combination of tucatinib, trastuzumab, capecitabine was used.

  • 3

    Median survival improved from 4.4 months to 10 months.

  • 4

    41% of patients were alive at 18 months.

  • 5

    Notable improvements in neurologic symptoms observed.

Original Source(s)

Small Phase II Study Examines Triplet Regimen for Patients With HER2-Positive Breast Cancer and Leptomeningeal Metastasis

  • by The ASCO Post Staff

  • April 8, 2026

Related Content

Antibody Oxidation’s Hidden Handedness Comes Into View

Integrated NMR and LC-MS analysis distinguishes elusive stereochemical forms of methionine oxidation in IgG1 Fc regions, offering a sharper tool for biologic drug quality control

  • April 8, 2026

  • 2 min
Analysis Shows Nearly 7% of Global Clinical Trials Are Impacted by Middle East Disruption

Oncology trials account for a substantial proportion of impacted activity, with non–small cell lung cancer representing the most affected indication, followed by breast cancer.

Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Bladder Cancer

As reported in The New England Journal of Medicine by Vulsteke et al, the phase III KEYNOTE-905/EV-303 trial has shown improved event-free and overall survival with the addition of perioperative enfor...